Intravitreal drug injections are one of the most common ophthalmic surgical procedures in everyday clinical practice. Drugs that block vascular endothelial growth factors are administered intravitreal. Intravitreal injections are performed under local drip anesthesia, but not all patients are provided with sufficient analgesia. Therefore, ophthalmologists reach for other analgesic drugs, such as non-steroidal anti-inflammatory drugs. In addition, inflammation is a common component in the pathogenesis of several macular diseases treated with intravitreal injections, such as exudative age-related macular degeneration. The article presents the mechanism of action of non-steroidal anti-inflammatory drugs and ophthalmological indications for their use. The effect of this group of drugs on the reduction of pain associated with intravitreal injections has been described. The beneficial effect of combination therapy with topical non-steroidal anti-inflammatory drugs on the frequency of administration of drugs blocking vascular endothelial growth factors and retinal morphology in patients with exudative age-related macular degeneration is presented. Conclusions. Non-steroidal anti-inflammatory drugs should be considered as an adjunct therapy to intravitreal injections of growth factor blocking agents. In addition, the analgesic effect of non-steroidal anti-inflammatory drugs justifies their use in everyday clinical practice in the peri-injection period, especially in patients experiencing increased pain in connection with repetitive procedures.